UniXell

UniXelI BIOTECHNOLOGY, established in 2021, is a company focused on developing a new generation of cell therapy drugs based on human pluripotent stem cell technology. Utilizing its proprietary technology platforms for the preparation, culture, differentiation, and gene editing of human pluripotent stem cells, the company is committed to technological R&D and product development in the field of stem cell therapy. Its R&D pipeline covers neurodegenerative diseases, rare diseases, and cancer. UniXelI BIOTECHNOLOGY has a solid foundation in cell therapy technology R&D, particularly achieving world-class levels in the R&D of cell therapies for neurological disorders, with multiple patents.